26CA.F IMMUNITYBIO INC. DL-0001
- Market cap
- EUR 6.41B
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 26CA.F undervalued?
Graham numberThe Graham number of IMMUNITYBIO INC. DL-0001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IMMUNITYBIO INC. DL-0001 fundamental analysis
No fundamental analysis for IMMUNITYBIO INC. DL-0001 yet.
IMMUNITYBIO INC. DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IMMUNITYBIO INC. DL-0001
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic ag…
Full company profileIMMUNITYBIO INC. DL-0001 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
IMMUNITYBIO INC. DL-0001 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 934K | 240K | 622K | 14.7M | 113M | 192M |
| Gross Profit | - | 240K | 622K | 14.7M | 113M | 190M |
| Operating Income | -330M | -351M | -361M | -344M | -256M | -279M |
| EBITDA | - | -352M | -479M | -264M | -224M | -1.26B |
| Net Income | -347M | -417M | -583M | -414M | -351M | -1.40B |
| EPS | -0.87 | -0.99 | -0.87 | -0.48 | -0.35 | -1.31 |
| Balance Sheet | ||||||
| Total Assets | 469M | 362M | 504M | 383M | 502M | 609M |
| Total Liabilities | 713M | 812M | 1.09B | 871M | 1.00B | 1.75B |
| Shareholders' Equity | -242M | -447M | -587M | -489M | -500M | -1.15B |
| Cash & Short-term Investments | 181M | 105M | 265M | 143M | 88.3M | 45.1M |
| Cash Flow | ||||||
| Operating Cash Flow | -274M | -338M | -367M | -391M | -305M | -290M |
| Capital Expenditure | 33.6M | 99.4M | 30.6M | 6.89M | 4.25M | 11.0M |
| Free Cash Flow | -308M | -437M | -397M | -398M | -309M | -301M |
| Ratios | ||||||
| ROA | -74.0% | -115.0% | -115.6% | -108.0% | -70.0% | -229.2% |
| Net Profit Margin | -37,129.6% | -173,569.6% | -93,761.4% | -2,804.8% | -310.2% | -726.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
IMMUNITYBIO INC. DL-0001 dividends
IMMUNITYBIO INC. DL-0001 has not paid dividends in the last 5 fiscal years.
Who owns IMMUNITYBIO INC. DL-0001
- Insiders 61.92%
- Institutions 20.01%
- Public & others 18.07%
- Shares outstanding 1.06B
- Free float 408M
IMMUNITYBIO INC. DL-0001 company profile
- Company name
- IMMUNITYBIO INC. DL-0001
- Ticker
- 26CA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 684
- Fiscal year end
- December
- Address
- 3530 John Hopkins Court, San Diego, CA, United States, 92121
- Phone
- 844 696 5235
- Website
- immunitybio.com
About IMMUNITYBIO INC. DL-0001
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
IMMUNITYBIO INC. DL-0001 management
10- Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., M.S., M.Sc.Founder, Executive Chairman and Global Chief Scientific & Medical Officer · born 1953
- Mr. Richard Gerald AdcockPresident, CEO & Director · born 1969
- Mr. David C. SachsChief Financial Officer · born 1978
- Ms. Regan J. LauerChief Accounting Officer · born 1970
- Dr. Barry J. Simon M.D.Chief Corporate Affairs Officer & Director · born 1965
- Dr. Enrique Diloné Ph.D., RACChief Technology Officer · born 1967
- Ms. Sarah SingletonChief Communications Officer & Head of Patient Advocacy
- Ms. Emily ArisonSenior Vice President of Human Resources
- Dr. Leonard S. Sender M.D.Chief Medical Officer of Liquid Tumors & Cell Therapy
- Dr. Sandeep K. Reddy M.D.Chief Medical Officer